Paper - WANFANG MED ONLINE

You Position: Home > Paper

Research progress of double-hit diffuse large B-cell lymphoma

( views:434, downloads:260 )

Author:: No author available

Journal Title:: Journal of Leukemia & Lymphoma

Issue:: 2

DOI:: 10.3760/cma.j.issn.1009-9921.2014.02.019

Key Word:: 二次打击淋巴瘤;淋巴瘤,大细胞,弥漫型;基因,myc;基因,bcl-2;基因,bcl-6;Double-hit lymphoma;Lymphoma,large-cell,diffuse;Genes,myc;Genes,bcl-2;Genes,bcl-6

Abstract： Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of non-Hodgkin's lymphoma.An uncommon subset with myc and either bcl-2 or bcl-6 rearrangement,also known as ‘double-hit’ lymphomas,is considered very aggressive clinical course and poor prognosis despite high-intensity chemotherapy.Recently,these lymphomas have received increased attention.This review explores the existing literatures for the involved genes with their functions,clinical features,diagnosis and treatment.

Reference

[1]徐晓度,季鸥.bcl-2家族调控的细胞死亡与恶性淋巴增殖性疾病[J].2012,(4).
[2]王国平,郗彦凤,李义,等.bcl-2与bcl-6在弥漫性大B细胞淋巴瘤中表达的研究[J].2009,(10).
[3]Visco,C.,Nielsen,O.,Pedersen,L.M.,etc.Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone[J].2012,30(28).
[4].Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?[J].2010.
[5]García-Suárez,J.,Flores,E.,Callejas,M.,etc.Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma[J].2013,160(4).
[6]Cuccuini,W.,Briere,J.,Mounier,N.,etc.MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation[J].2012,119(20).
[7]Clawson SM,Wolf M,Barrans SL,etc.A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).[J].2008,112(6).
[8]Kerry J. Savage,Nathalie A. Johnson,Susana Ben Neriah.MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy[J].2009,114(17).
[9]Ryan D. Morin,Maria Mendez-Lago,Andrew J. Mungall,etc.Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma[J].2011,476(Aug.18 TN.7360).
[10]Chadburn A,Shaknovich R,Hatzi K,etc.A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.[J].2009,113(15).
[11]Johnson NA,Gascoyne RD,Horsman DE,etc.Prognostic significance of secondary cytogenetic alterations in follicular lymphomas.[J].2008,47(12).
[12]Ken Ohmachi,Kiyoshi Ando,Michinori Ogura,etc.Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma[J].2010,101(9).
[13]Maeshima AM,Taniguchi H,Mori M,etc.Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with [J].2010,92(5).
[14]Johnson,N.A.,Slack,G.W.,Savage,K.J.,etc.Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone[J].2012,30(28).
[15]Swerdlow,S.H.,Pillai,R.K.,VanOss,S.B.,etc.Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas[J].2013,37(3).
[16]Shimura Y,Tsutsumi Y,Nishida K,etc.Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.[J].2011,39(8).
[17]Okamoto M,Miura I,Hirano M,etc.Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14; 18) and 8q24/c-MYC translocations.[J].2009,23(4).
[18]EricMartin,S.,Dunleavy,K.,Johnson,J.,etc.A cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype[J].2012,97(5).
[19]Kolman OK,Chen Y,Snuderl M.B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.[J].2010,34(3).
[20]Patmore R,Turner K,Barrans S,etc.Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.[J].2010,28(20).
[21]T J, McDonnell,S J, Korsmeyer.Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18).[J].1991,349.
[22]Harousseau JL,Garand R,Milpied N,etc.The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14; 18) and 8q24/c-MYC rearrangement.[J].2007,92(10).
[23]Iqbal J,Meyer PN,Smith LM,etc.BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.[J].2011,17(24).
[24]Li,S.,Lin,P.,Fayad,L.E.,etc.B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18) (q32;q21): An aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome[J].2012,25(1).
[25]Siebert R,Aukema SM,van Imhoff GW,etc.Double-hit B-cell lymphomas.[J].2011,117(8).